FSTX - F-star Therapeutics up 18% as it extends end date of merger with invoX Pharma
- F-star Therapeutics ( NASDAQ: FSTX ) is up 18% in premarket trading after announcing that it is extending the end date of its planned merger with invoX Pharma.
- The extension is to further hammer out negotiations with the Committee on Foreign Investment in the United States om terms for a mitigation agreement.
- The date has been extended to Feb. 8.
- invoX Pharma, a unit of China's Sino Biopharmaceutical Limited ( OTCPK:SBHMY ) ( OTCPK:SBMFF ), agreed to acquire F-star ( FSTX ) for $161M cash.
- The two companies will also use the extra time to iron out details of the tender offer.
- The parties extended the deadline before in late December .
For further details see:
F-star Therapeutics up 18% as it extends end date of merger with invoX Pharma